Get the Stockscreener App
878.13
0.99%
7.7612
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $878.13, with a volume of 1.62M.
It is up +0.99% in the last 24 hours and up +13.67% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
See More
Previous Close:
$870.37
Open:
$876.53
24h Volume:
1.62M
Relative Volume:
0.43
Market Cap:
$827.20B
Revenue:
$40.86B
Net Income/Loss:
$8.37B
P/E Ratio:
94.93
EPS:
9.25
Net Cash Flow:
$-2.28B
1W Performance:
+8.38%
1M Performance:
+13.67%
6M Performance:
+13.84%
1Y Performance:
+21.18%
1-Day Range:
$869.62
$889.36
1-Week Range:
$801.75
$889.36
52-Week Range:
$711.40
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
878.87 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
86.96 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.98 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
192.17 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
88.25 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly reports sustained Crohn's disease treatment success - Investing.com
Eli Lilly & Co: Buy Rating Backed by Strategic Growth and Strong Financial Guidance - TipRanks
Eli Lilly reports sustained Crohn's disease treatment success By Investing.com - Investing.com UK
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years - PR Newswire
Analysts recommendations: Aj Bell, GSK, Anglo American, Eli Lilly, Expedia… - Marketscreener.com
Eli Lilly and Co (LLY) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly Earnings: GLP-1 Market Growth Looks Solid - Morningstar
Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat - Morningstar
Why Eli Lilly Shrugged Off its Weight-Loss Disappointment - Investor's Business Daily
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript - The Motley Fool
Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight (LLY) - Seeking Alpha
Eli Lilly, Novo Nordisk sold more than $40 billion in GLP-1 drugs in 2024 - Sherwood News
A Closer Look at Eli Lilly's Options Market Dynamics - Benzinga
Eli Lilly and Company (NYSE:LLY) Trading Up 4.1%Should You Buy? - MarketBeat
What Are Wall Street Analysts' Target Price For Eli Lilly Stock? - Barchart
Lilly reassures investors that weight-loss drug demand is strong, shares rise - Reuters
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound - FiercePharma
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines - AOL
Eli Lilly annual profit outlook tops expectations; stock gains - Investing.com
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - 21 Alive News
Lilly’s profit doubles in fourth quarter, driven by Mounjaro and Zepbound sales - WISH TV Indianapolis, IN
Eli Lilly’s Full-Year Profit Views in Line After Recent Misses - Bloomberg
Lilly reports robust Q4, full-year earnings - Inside INdiana Business
Why Eli Lilly Stock Popped on Thursday - The Motley Fool
Eli Lilly Stock Rises After Profit, Outlook Top Expectations - Kiplinger's Personal Finance
Lilly’s profit forecast bring investors some relief amid Zepbound miss - PharmaLive
Market movers: Ford, Peloton, Skyworks Solutions, Eli Lilly... - Proactive Investors USA
Eli Lilly’s Net Income Doubles And Its Revenue Grows 45% - Baystreet.ca
Eli Lilly revenue misses expectations despite strong growth in Mounjaro, Zepbound - Proactive Investors USA
Eli Lilly (LLY) Stock Rises on Strong Q4 Earnings and Bullish 2025 Outlook – market - HPBL
Zepbound sales keep soaring, even as weight loss drug growth slows - Quartz
Eli Lilly Full-Year Earnings Meet Expectations Amid GLP-1 Inventory Challenges – market - HPBL
Eli Lilly (LLY) Reports Blockbuster Q4 Revenue Growth Fueled by Mounjaro and Zepbound Sales - HPBL
Eli Lilly expects to beat profit forecasts on obesity drug demand - Financial Times
Eli Lilly forecasts 2025 profit growth after recent weight-loss drug worries - The Globe and Mail
Weight-loss drugs swell revenues at Eli Lilly - ShareCast
Eli Lilly Posts Mixed Q4 Results; Fiscal 2025 Guidance Reaffirmed - Yahoo Finance UK
Lilly issues 2025 profit view as it steers for revenue boost - MSN
Eli Lilly: 4th quarter consensus beaten -February 06, 2025 at 08:11 am EST - Marketscreener.com
Lilly Profit View ‘Enough to Pacify Investors’ After Sales Miss - BNN Bloomberg
Eli Lilly CEO reveals latest developments in Alzheimer's research - Fox Business
Eli Lilly Reports Q4 2024 Earnings: EPS at $4.88, Revenue Hits $13.53 Billion, Missing Analyst Estimates - GuruFocus.com
Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs - Yahoo Finance UK
Lilly forecasts 2025 profit above estimates on weight-loss drug strength - Business Standard
Eli Lilly stock rises on Q4 2024 beat (update) (LLY:NYSE) - Seeking Alpha
Eli Lilly (NYSE:LLY) Reports Q4 In Line With Expectations, Full-Year Outlook Slightly Exceeds Expectations - Investing.com Canada
UPDATE: Lilly reports robust Q4, full-year earnings - Indianapolis Business Journal
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected - NBC Philadelphia
LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments - TipRanks
Eli Lilly Reports Q4 Worldwide Mounjaro Revenue Increased 60% To $3.53 Billion -February 06, 2025 at 07:15 am EST - Marketscreener.com
Eli Lilly’s Q4 2024 Revenue Surges by 45% to $13.53 Billion - The Tokenist
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):